Interstitial Cystitis (IC) Market Insights, Epidemiology and Market Forecast-2027
Albany, NY -- (SBWire) -- 09/04/2018 --Interstitial Cystitis(IC), also called as Painful Bladder Syndrome, is a chronic condition causing bladder pressure, bladder pain and sometimes pelvic pain. The pain ranges from mild discomfort to severe levels. Bladder is a hollow, muscular organ that stores urine. The bladder expands until it is full and then give signals to the brain that it is time to urinate, communicating through the pelvic nerves. IC can be of two types: Non-Ulcerative and Ulcerative. Non-Ulcerative is found in 90% of the population suffering from Interstitial Cystitis. It is characterized by pinpoint hemorrhages called as glomerulations. Ulcerative IC is mainly characterized by Hunner's ulcers and the patches that bleed on bladder walls. However, IC was considered as a rare disease; this came from a situation of underdiagnosis and misunderstandings about the nature of the IC. It was not until late 1970s, when researchers proved that the vast majority of patients with IC has no Hunner lesions.
According to the report of DelveInsight "Interstitial Cystitis (IC) Market Insights, Epidemiology and Market Forecast-2027" total prevalent population of IC in the 7 Major Markets was estimated to be 8,457,111 in 2016 that is expected to increase. DelveInsight's estimates suggest higher prevalence of Interstitial Cystitis in the United States with 4,951,841 prevalent cases in 2016. Higher prevalence of the disease is observed among the females as compared to males. Among the European countries, Germany had the highest prevalent population of Interstitial Cystitis with 843,523 cases, followed by France which had prevalent population of 644,528 in 2016. On the other hand, Spain had the lowest prevalent population of 492,169 in 2016 while Japan had 249,867 prevalent cases of Interstitial Cystitis in 2016. The United States has highest prevalent population of Interstitial Cystitis (IC) than EU5 (Germany, France, Spain, Italy and UK) and Japan. Furthermore, the estimates suggest overall diagnosed prevalence of moderate IC was the maximum, followed by the mild and severe and is subjected to increase in the coming years.
Market analysis study carried out for the period of 2016-2027 demonstrates that the Market size of Interstitial Cystitis was USD 1,574.9 million in 2016 in 7MM. The current therapeutic landscape of IC in the US can be divided into two major categories based on the route of administration and the approved usage for the condition. These are: Oral Therapies and Intravesical Instillations. Cystoscopy with hydro distention is also used as a therapy in addition to its utility as a diagnostic tool. Oral regimens are used either as first-line or second-line therapies for IC. Among Oral therapies, different classes of medication are used. The market of IC is dominated by various off-label drugs. These are Painkillers (including OTCs, Non-Narcotics, and Narcotics), Antidepressants (including NRIs, SSRIs and SNRIs), Antiepileptic, Antihistamines, Immunosuppressant, and L-arginine. Among orally administered therapies, only Elmiron (Pentosan polysulfate sodium; Janssen Pharmaceuticals) is approved by U.S. Food and Drug Administration (FDA) for the treatment of IC. The dynamics of Interstitial Cystitis market is anticipated to change during the forecasted period. Owing to the expected launch of emerging therapies during the forecasted period (2018-2027), the market size is expected to increase in subsequent years.
Emerging Drugs Analysis
Therapies such as Mirabegron (Astellas Pharma), ASP6294 (Astellas Pharma), LP-08 (Lipella Pharmaceuticals) and GRT6010 (Grünenthal) are expected to enter the Interstitial Cystitis market in coming years, which shall lead to a significant rise in the market revenue during the forecast period (2018-2027). Mirabegron (Astellas Pharma), an orally bioavailable agonist of the human beta-3 adrenergic receptor (ADRB3), is believed to generate highest revenue amongst all the other upcoming therapies. As per DelveInsight analysis, Mirabegron is expected to launch in 2021. Apart from these emerging drugs, AQX-1125 (Rosiptor; Aquinox Pharmaceutical) was also being developed for the treatment of IC. Despite the good safety and efficacy results of the drug in Phase II trial, AQX-1125 failed the Phase-III clinical trial. Hence, the company has halted all further development activities with Rosiptor.
The report covers the descriptive overview of Interstitial Cystitis, explaining its causes and currently available Therapies. Comprehensive insight has been provided into the epidemiology of the Interstitial Cystitis and its treatment in the 7 MM, covering the United States, EU5 (Germany, Spain, France, Italy, the UK) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Interstitial Cystitis are provided, along with assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of historical and forecasted Interstitial Cystitis market is included in the report, covering drug outreach in 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Interstitial Cystitis market.
For Sample Pages : https://www.delveinsight.com/report-store/interstitial-cystitis-market-insight-epidemiology-and-market-forecast
Reasons to buy:
1.The report will help in developing business strategies by understanding trends shaping and driving the Interstitial Cystitis market.
2.To understand the future market competition in the Interstitial Cystitis market and Insight reviews of the key market drivers and barriers.
3.Identification of strong upcoming players in the Interstitial Cystitis market will help in devising strategies that will help in getting ahead of competitors.
4.In-depth understanding of the pipeline development and recent happenings will provide a competitive edge over competitors.
And many others……………
Table of Contents
1. Key Insights
2. Interstitial Cystitis: Market Overview at a Glance
3. Interstitial Cystitis (IC): Disease Background and Overview
4. Epidemiology and Patient Population
5. 7MM Total Prevalent Patient Population of Interstitial Cystitis
6. 7MM Total Diagnosed Prevalent Patient Population of Interstitial Cystitis
7. Country Wise-Epidemiology of Interstitial Cystitis
7.1. United States
7.2. EU5 Countries
7.7. United Kingdom
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Marketed Drugs
10.1. Elmiron: Janssen Pharmaceutical
10.3. RIMSO-50: Mylan Pharmaceutical
10.4. Cystistat: Bioniche Life Sciences Inc
10.5. Gepan instill: Pohl-Boskamp GmbH
10.6. Uracyst: Stellar Pharmaceuticals
10.7. Hyacyst: Syner-Med
10.8. iAluRil: Aspire Pharma
11. Emerging Therapies
11.1. Key Cross Competition
11.2. AQX-1125: Aquinox Pharmaceuticals
11.3. Mirabegron: Astellas Pharma Global Development
11.4. ASP6294: Astellas Pharma Global Development
11.5. LP-08: Lipella Pharmaceuticals
11.6. GRT6010: Grünenthal
12. Interstitial Cystitis: 7 Major Market Analysis
13. The United States Market Outlook
14. EU-5 Countries: Market Outlook
16. Market Drivers
17. Market Barriers
19. DelveInsight Capabilities
*** For detailed TOC request for sample pages.
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. We support companies by providing end to end comprehensive solutions to improve their performance and in making long lasting decision for their businesses
We advise leading decision makers on their critical issues and opportunities; Research & Development, Strategy Making, Commercial, Operations, Competitive Intelligence, Competitive Landscaping and Mergers & Acquisition across all the Pharma and Biotech industries and geographies. We serve our clients by delivering practical and enduring results, and equipping our clients to grow and lead.
Media Relations Contact
Digital marketing specialist
View this press release online at: http://rwire.com/1040840